Patients received one or two injections depending on the condition. Men with ED received a intracavernosal injection, men with PD received injections directly into tunical plaques under ultrasound guidance. The SUI patient received an injection into urethral submucosa, distal to the bladder neck, using a pediatric cystoscope and transurethral injection needle. Researchers injected the PRFM within 10 minutes of activating the clotting cascade with calcium chloride. Administering injections within 10 minutes prevented the solution from washing out of the target area.
The study found 4 participants experienced mild pain, one reported bruising, and no major adverse events. PRFM is a second generation PRP preparation that has higher hematocrit levels than pure PRP. The increase in hematocrit levels is known to increase pain at injection site, but benefits the reconstruction of damaged vasculature by creating a scaffold for tissue ingrowth.
The trail was designed to assess safety and efficacy of PRP injections. IIEF-5 scores increased an average of 4.14 points after PRP treatment. Nine of the 11 PD participants reported subjective improvement in the degree of penile curvature. The SUI patient experienced a 50% reduction in episodes of incontinence. Future trials would benefit from reporting platelet counts at baseline and in the final solution, as well as the addition of a control group to assess placebo.³